Bionano Genomics, Inc. splits its revenue into 4 lines in its filings. The largest line in Q2 of fiscal 2026, the quarter ended Jun 30, 2026 was Consumable Revenue at $4.3 million, 52% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
30
|
8
|
7
|
8
|
7
|
7
|
6
|
8
|
6
|
| Consumable Revenue |
16
+17.9%
share 51.8%
|
4
+30.8%
share 52.4%
|
4
+20.1%
share 58.3%
|
4
+7.8%
share 46.2%
|
4
+13.2%
share 51.2%
|
3
share 48.7%
|
3
share 50.3%
|
3
share 41.7%
|
3
share 54.9%
|
| Instrument Revenue |
7
+16.3%
share 24.1%
|
2
+45.6%
share 24.9%
|
1
+39.6%
share 14.4%
|
3
-3.4%
share 33.4%
|
2
+14.1%
share 22.0%
|
1
share 20.8%
|
1
share 10.7%
|
3
share 33.7%
|
1
share 23.4%
|
| Software Revenue |
5
-17.9%
share 17.6%
|
1
-16.1%
share 16.8%
|
1
-40.4%
share 18.4%
|
1
-21.9%
share 14.7%
|
2
+21.5%
share 20.9%
|
2
share 24.3%
|
2
share 32.0%
|
1
share 18.3%
|
1
share 20.9%
|
| Product And Service Other |
2
+35.9%
share 6.5%
|
0
+13.0%
share 5.8%
|
1
+30.9%
share 8.9%
|
0
-11.3%
share 5.7%
|
0
+732.7%
share 5.9%
|
0
share 6.3%
|
0
share 7.0%
|
1
share 6.3%
|
0
share 0.9%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Laboratory Analytical Instruments (SIC 3826)
- Listed as
- BNGO (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1411690
- Former names
- BioNano Genomics, Inc (until Oct 20, 2021); Bionano Genomics, Inc (until Oct 20, 2021); BioNanomatrix Inc (until Mar 24, 2011)
Other Laboratory Analytical Instruments companies
- Agilent Technologies, Inc. A
- Waters Corp /DE/ WAT
- Illumina, Inc. ILMN
- Mettler Toledo International INC/ MTD
- Revvity, Inc. RVTY
- Avantor, Inc. AVTR
- Bio-Rad Laboratories, Inc. BIO
- Bruker Corp BRKR
Source: SEC EDGAR filings. This is company-reported data, not investment advice.